Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis. Ruxolitinib will remain a main stay in the treatment of MPN patients due to its effective therapeutic benefits. However, there have been instan...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	myeloproliferative neoplasm JAK2-V617F ruxolitinib resistance Hsp90 inhibitior type I JAK2 inhibition
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1430833/full